The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Jan 2016 15:00

RNS Number : 9122K
Diurnal Group PLC
05 January 2016
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Diurnal Group Plc.

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

No

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

No

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

No

An event changing the breakdown of voting rights

No

Other (please specify):

Placing

Yes

3. Full name of person(s) subject to thenotification obligation: iii

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

24 December 2015

6. Date on which issuer notified:

29 December 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

5%, 10%, 11% & 12%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00BDB6Q760

0

0

6,527,777

12.50%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

6,527,777

12.50%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Invesco Asset Management Ltd - 6,527,777

Proxy Voting:

10. Name of the proxy holder:

Invesco Limited

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

14. Contact name:

Philippa Holmes

15. Contact telephone number:

01491 417 000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUMAGUPQGCA
Date   Source Headline
9th Jan 20187:00 amRNSPositive results from Alkindi food matrix study
9th Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
5th Jan 20185:06 pmRNSIssue of Equity
5th Jan 20185:04 pmRNSReplacement - Director Dealings
5th Jan 20181:19 pmRNSDirector Dealings
19th Dec 201712:53 pmRNSHardman Research: Alkindi®: On route to Europe
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
15th Dec 201712:11 pmRNSCHMP positive opinion for Alkindi® (Infacort®)
8th Dec 201711:30 amRNSTotal Voting Rights
29th Nov 201712:20 pmRNSDirector/PDMR Shareholding
21st Nov 201712:00 pmRNSResult of AGM
9th Nov 20176:19 pmRNSDirector Dealing and Issue of Equity
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
13th Oct 20179:00 amRNSPosting of Annual Report and AGM Notice
15th Sep 20177:00 amRNSInfacort® data published in Clinical Endocrinology
14th Sep 20177:15 amRNSHardman Research: Ready to press the button
7th Sep 20172:51 pmRNSDirector Dealings
6th Sep 20177:00 amRNSGrant of first US patent for Chronocort®
6th Sep 20177:00 amRNSResults for the year ended 30 June 2017
14th Aug 201710:00 amRNSNotice of Final Results
15th Jun 20177:00 amRNSFirst Patient Dosed in US Infacort Clinical Trial
18th May 20177:00 amRNSGrant of first US patent for Infacort
8th May 201710:03 amRNSDirector/PDMR Shareholding
27th Mar 20177:15 amRNSHardman Research:Commercial and development update
20th Mar 20177:00 amRNSInterim Results for the 6 Months Ended 31 Dec 2016
16th Mar 20177:00 amRNSLaunch of a European Patient Access programme
2nd Mar 20177:00 amRNSMarketing and Distribution Agreement
1st Mar 20177:00 amRNSNotice of Interim Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUpdate on Commercial Pre-Launch Activities
19th Jan 20177:15 amRNSHardman Research: Infacort® - On track to market
17th Jan 20173:30 pmRNSDirector Dealings
16th Jan 20177:00 amRNSDirectors' Dealings
12th Jan 20177:00 amRNSAppointment of Chief Financial Officer
4th Jan 20173:38 pmRNSHolding(s) in Company
20th Dec 201612:08 pmRNSSubmission of Infacort® European PUMA Application
23rd Nov 201611:30 amRNSResults of Annual General Meeting
21st Nov 20167:00 amRNSFirst Patient Dosed in Testosterone Trial
9th Nov 20169:36 amRNSDirector/PDMR Shareholding
27th Oct 20167:15 amRNSHardman Research: Get the Rhythm
12th Oct 20167:00 amRNSFull Infacort Phase III Data Analysis
12th Oct 20167:00 amRNSFinal Results June 2016
12th Sep 20167:00 amRNSNotice of Results
11th Jul 20167:00 amRNSPositive headline data Infacort pivotal study
12th Apr 201612:15 pmRNSGrants of options and award of conditional shares
30th Mar 20167:00 amRNSHalf Yearly Report
22nd Mar 20163:00 pmRNSNotice of Results
29th Feb 20167:00 amRNSFirst patient dosed in Chronocort® pivotal study
19th Jan 20163:32 pmRNSHolding(s) in Company
5th Jan 20163:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.